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Abstract
Introduction: There are growing concerns about the emergence of resistance to artemisinin-based combination therapies
(ACTs). Since the widespread adoption of ACTs, there has been a decrease in the systematic surveillance of antimalarial drug
resistance in many malaria-endemic countries. The aim of this work was to test whether data on travellers returning from
Africa with malaria could serve as an additional surveillance system of local information sources for the emergence of drug
resistance in endemic-countries.
Methodology: Data were collected from travellers with symptomatic Plasmodium falciparum malaria returning from
Senegal (n = 1,993), Mali (n = 2,372), Cote d’Ivoire (n = 4,778) or Cameroon (n = 3,272) and recorded in the French Malaria
Reference Centre during the period 1996–2011. Temporal trends of the proportion of parasite isolates that carried the
mutant genotype, pfcrt 76T, a marker of resistance to chloroquine (CQ) and pfdhfr 108N, a marker of resistance to
pyrimethamine, were compared for travellers and within-country surveys that were identified through a literature review in
PubMed. The in vitro response to CQ was also compared between these two groups for parasites from Senegal.
Results: The trends in the proportion of parasites that carried pfcrt 76T, and pfdhfr 108N, were compared for parasites from
travellers and patients within-country using the slopes of the curves over time; no significant differences in the trends were
found for any of the 4 countries. These results were supported by in vitro analysis of parasites from the field in Senegal and
travellers returning to France, where the trends were also not significantly different.
Conclusion: The results have not shown different trends in resistance between parasites derived from travellers or from
parasites within-country. This work highlights the value of an international database of drug responses in travellers as an
additional tool to assess the emergence of drug resistance in endemic areas where information is limited.
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Introduction
A decline in artemisinin efficacy has recently been confirmed in
several regions in Southeast Asia [1,2,3]. Concerns are growing
about the potential for this artemisinin resistance to spread to sub-
Saharan Africa, as it has previously been described for other
antimalarial drugs. Indeed, resistance to chloroquine (CQ) and
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sulfadoxine-pyrimethamine (SP) emerged relatively quickly after
their introduction and subsequently spread from Asia to Africa
[4,5]. Early detection of decreasing drug efficacy and the
consequent updating of drug policies are crucial elements in the
strategy to prevent the emergence or delay the spread of drug
resistance [6,7]. In recent years, considerable effort has been made
to improve epidemiological antimalarial resistance surveillance in
countries with limited resources. Therapeutic efficacy studies
remain the gold standard for guiding drug policy, as they take into
account the complex interactions between the host, parasite and
drug [8]. However, many settings in endemic countries lack the
financial resources necessary to maintain a sustainable, accurate
and reliable antimalarial resistance surveillance system, resulting in
gaps in the spatial and temporal available information.
In recent years, globalization and a substantial increase in
international travel and population mobility, have provided the
potential for the rapid spread of infectious diseases and antimi-
crobial resistance [9]. More than 900 million international
journeys are undertaken annually and this figure has been
consistently rising over the years (United Nations World Tourism
Organization: UNWTO).
Malaria is endemic in over 100 countries and represents an
important infectious disease threat for these nations. Of the 125
million people travelling to malaria endemic countries each year,
approximately 10,000 malaria infections were reported worldwide
in returning travellers in 2010. Under-reporting is thought to be
substantial and, hence, this number may, in reality, exceed 30,000
[10]. In Europe, a 10-fold increase in imported infections was
reported from 1970 to 2000 (from 1,500 to about 15,000 cases)
before decreasing to about 6,000 cases in 2010 (http://data.euro.
who.int/cisid); most of these cases were reported in France or the
United Kingdom [11]. Travellers who return from endemic
countries infected with malaria often present with low immunity
against the parasites and there is no risk of re-infection, so they are
a particularly valuable source of information.
In fact, historically, the emergence of CQ resistance in Africa
was mainly detected through surveillance of travellers (Figure 1,
Table 1). The current study was undertaken to test the idea that
surveillance of parasites from travellers can be used to accurately
assess the evolution of antimalarial drug resistance and provide
complementary information to existing monitoring. As a proof of
concept, the aim was to compare trends in molecular and in vitro
markers of drug resistance observed in the imported malaria
population with the trends described in field studies.
Materials and Methods
Data Collection
The studies were conducted by the National Reference Centre
for Malaria (CNR), Paris, France and investigators from the four
endemic countries, in collaboration with the WorldWide Antima-
larial Resistance Network (WWARN).
Data from travellers. Data were collected from travellers
with symptomatic Plasmodium falciparum malaria returning from
malaria-endemic countries during the period 1996–2011. These
cases were reported to the French CNR by one of the 80 hospitals
participating in the sentinel network for malaria which covers
about half of the cases diagnosed in France. All the travellers
included in this study must have visited a malaria-endemic African
country in the two months prior to diagnosis and presented with a
P. falciparum infection biologically confirmed by thin and thick
blood smear. Basic demographic, epidemiologic, clinical, and
parasitological information as well as response to treatment,
previous malaria infection and travel history information were
systematically reported. Blood samples were only collected from
hospitals which document anti-malarial drug resistance on a
systematic basis in all Plasmodium positive diagnosis, before
treatment, for molecular and in vitro analyses.
Molecular markers associated with resistance to CQ and
pyrimethamine and CQ susceptibility in vitro were the tools used
to compare antimalarial drug resistance trends between travellers
and field studies.
No informed consent was required for this study as the
procedures described here were part of the French national
surveillance system of malaria. In 2006, the Commission Nationale
de l’Informatique et des Liberte´s (CNIL), France, approved the
electronic-based utilisation of patient-level data collected through
the CNR’s questionnaire. We did not receive ethical approval or
waiver to perform this secondary research on samples collected as
a part of government surveillance for communicable diseases (Loi
nu 2004-806 art.16, 21, 9 August 2004, Journal Officiel 11 August
2004). However, ethical aspects have been respected according to
the French regulation (article L.1211-2, L.1111-7, L.1413-4 and
L.1413-5 Code de la Sante´ Publique). Also an information note,
which explained that the collected blood samples could be used for
further research analyses, was provided to the patients who had
the possibility to refuse; and the samples were anonymised for this
study.
Data within-country. A literature review was performed in
PubMed for publications on malaria from African endemic
countries during the period 1996–2011. The search terms [country
name+(pfcrt OR chloroquine resistance)] and [country name+(DHFR
OR sulfadoxine-pyrimethamine resistance OR sulfadoxine pyri-
methamine resistance)] were used.
After performing a sample size calculation (see below sample
size calculation section), four African countries, Senegal, Mali,
Cote d’Ivoire and Cameroon were included in this study. They
had sufficiently large numbers of both travellers and field
molecular data, from 1996–2011, for a meaningful comparison.
The collaboration of investigators within the four targeted
countries, facilitated by WWARN, enabled the collation and
standardisation of published field data and the identification and
standardisation of unpublished field data. The field studies used for
the analyses are summarized in Table 2.
Laboratory Analysis of Parasites
Molecular analysis. Two molecular markers, pfcrt 76 for CQ
resistance and pfdhfr 108 for pyrimethamine resistance, were used
in this study to compare the trends between travellers and field
data. Although the presence of these two markers does not
perfectly correlate with treatment failure, each is a good proxy of
the intrinsic resistance of the parasite [12,13]. They are used here
as a proof of concept since they have been widely and consistently
collected in both field studies and travellers surveillance over the
period of interest. Due to the availability of travellers’ data, the
time period of 2000–2011 was studied for pfcrt 76T, while the time
period of 1996–2011 was used for pfdhfr 108N.
For molecular analyses of parasites from travellers, DNA was
extracted from blood samples of P. falciparum, using the QIAamp
DNA Mini Kit, QiagenH before 2008 and the MagNA Pure LC
DNA Isolation Kit I, Roche after 2008. PCR and subsequent
allele-specific restriction analyses were performed to identify
polymorphic codons of interest at the pfcrt 76 locus (Lys to Thr)
and the pfdhfr 108 locus (Ser to Asn) [14].
For field studies, the genotyping methods differed slightly
between studies. The detailed method for each study was
described in the corresponding publication (see Table 2 for the
references to the studies).
Surveillance of Travellers for Tracking Resistance
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Only ‘‘pure’’ pfcrt 76T and pfdhfr 108N infections among the
total number of samples tested were included to improve
comparability of the allele prevalence calculated between studies.
Indeed, genotyping methods for detecting mixed infections vary in
sensitivity across studies. There is not clear evidence that patients
living in endemic countries are more likely to carry mixed alleles
(mutant and sensitive) than travellers returning from endemic
countries as the number of mosquitoes’ bites is not the only factor
to consider and the presence of mixed infections is possible after
only one bite [15].
In vitro assay. For the in vitro susceptibility tests, only data
from Senegal were analysed in this study because there were
sufficient available data for parasites from both the travellers and
within-country isolates over the complete period of interest.
For susceptibility tests of parasites from travellers, the following
methods were used. The batches of plates were validated on the
CQ-susceptible 3D7 reference strain and the CQ-resistant W2
reference strain using the standard 42-hour 3H-hypoxanthine
uptake inhibition method in controlled atmospheric conditions in
the incubator (5% CO2, 10% O2 and 85% N2) [16,17]. The
isotopic microtests were performed, aliquoting 200 ml/well of the
suspension of fresh parasitized erythrocytes into 96-well plates pre-
dosed with CQ. Radioactivity incorporated by the parasites was
measured using a scintillation counter. The CQ susceptibility was
calculated as the 50% inhibitory concentration (IC50) of CQ of the
isolates tested [18,19]. The drug concentration that inhibited 50%
of parasite growth (IC50) was estimated by using nonlinear
regression to fit an inhibitory sigmoid Emax model [20]. The In
Vitro Analysis and Reporting Tool (IVART) enabled the transfor-
mation, standardization and analysis of the data [21].
For within-country surveys, the in vitro methods differed
between studies and were described in the publications, which
are referenced in Table 2. However, the measurement of the drug
susceptibility of fresh P. falciparum parasites was mainly performed
by isotopic assays using the 3H-hypoxanthine uptake inhibition
method. The in vitro CQ susceptibility was determined by a P.
Figure 1. Map of Africa illustrating the emergence of CQ resistance in East, Central and West Africa detected through travellers’
surveillance from the late 1970s to the early 1980s. The dates of detection of index cases are displayed. The red arrows show the spread of
antimalarial resistance from East Africa to West Africa.
doi:10.1371/journal.pone.0077775.g001
Table 1. First published cases of CQ resistance in Africa through travellers’ surveillance*.
Country Date case Date published Country of detection Reference
Kenya 1978 1979 Denmark [29]
East Africa (Kenya-Tanzania) 1975 1979 United States [30]
Democratic Republic of the Congo (Zaire) 1982 1983 United States [31]
Burundi 1983 1984 France [32]
Republic of the Congo 1984 1985 France [33]
Cameroon 1984 1985 France [34]
Angola 1984 1984 Denmark [35]
Gabon 1985 1986 United States [36]
Benin 1986 1986 France [37]
Senegal 1986 1987 Sweden [38]
Cote d’Ivoire 1987 1988 France [39]
Mali 1987 1988 France [40]
*The within-country studies which detected the emergence of CQ resistance in other parts of Africa during this time period are not shown here.
doi:10.1371/journal.pone.0077775.t001
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Table 2. Summary of the molecular and in vitro field studies in the four endemic countries included in the analysis (both
published and unpublished).
Country Site Age population Year of study Reference
Molecular marker analysis
Pfcrt 76 Senegal Pikine $5 ya 2000 [41]
Pikine $18ya 2001 [42]
Thiadiaye Pregnant women 2002 [43]
Dakar 3–65ya 2002 [44]
Pikine $3ya 2004 [45]
Dakar All 2004 [46]
Thies All 2007 [47]
Dakar All 2009–10 [48]
Central Senegal (3 districts : Mbour,
Fatick, Bambey) and Southern Senegal
(3 districts : Tambacounda, Velingara,
Saraya)
,10 ya 2009–11 [49]
Dakar all 2010–2011 Pradines, unpublished data
Mali Kolle ,5 ya 2002–03 [50]
Bougoula-Hameau .6 mths 2002–04 [51]
Bancouma, Monteourou, Bandiagara,
Faladie, Koulikoro Ba, Sirakoro-meg,
Niena, Kolebougou, Markakoungo,
Dimbal, Kafana, Siekorole, Toguel,
M’pessoba Banamba, N’debougou
all 2002–04 [52]
Kangaba et kela .6 mths 2001–03 [53]
Bandiagara, Faladje Kolle Pongenon all 2010 Djimde´, unpublished data
Cote d’Ivoire Anonkoua-koute (Abidjan), Ayame´,
Dabakala
all 2003–08 Ako, unpublished data
Bonoua and Samo ,5 ya 2005 [54]
Abidjan (2 districts: Yopougon and
Adjame´)
Children 2006 [55]
Adzope Children 2007 [56]
Cameroon Maroua, Ndop, Bafoussam, He´ve´cam ,5 ya 2000–01 [57]
Yaounde´ .12 ya 2000–01 [58]
Garoua, Yaounde, Mutengene ,5 ya 2004–06 [59]
Yaounde´, Mfou (suburb of Yaounde´) All ages 2005–08 [60]
Pfdhfr 108 Senegal Dielmo, Sine Saloum All 1996–99 [61]
Pikine, Tambacounda, Thies $5 ya 2000–03 [62]
Dakar 3–65 ya 2002 [44]
Dakar ,5 ya 2006–08 [63]
Dakar all 2009–10 [47]
Mali Tieneguebougou 2–12 ya 1996 [64]
Kidal All 1999 [65]
Bandiagara 5–15 ya 2000 [66]
Kolle ,5 ya 2002–03 [50]
Bongoula-Hameau .6 mths 2002–04 [50]
Kolokani ,5 ya 2006–07 [67]
Cote d’Ivoire Yopougon ,5 ya 2000–01 [68]
Anonkoua-koute (Abidjan), Ayame´,
Dabakala
2003–08 Ako, unpublished data
Bonoua and Samo ,5 y 2005 [54]
Abidjan (2 districts: Yopougon and
Adjame´)
Children 2006 [55]
Adzope Children 2007 [56]
Cameroon Bertoua, Douala, Eseka, Yaounde ,5 ya 1999 [69]
Surveillance of Travellers for Tracking Resistance
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falciparum Lactate DeHydrogenase (pLDH) ELISA assay in four
studies.
Statistical Analysis
Sample size calculation. In order to select eligible countries
with enough data per year for significant molecular analysis, a
sample size calculation was first performed. The basic comparison
of the trends used a simple logistic regression model. The
prevalence of isolates from traveller samples that carried a mutant
allele (Pt) or from studies on field samples (Pf) was the metric used.
In the models: S.
logit(Pt)~atzStX
logit(Pf )~afzSfX
where X is the time covariate and a the intercept, the null
hypothesis of equal temporal slopes was tested [22]. That is,
Ho : slope in travellers0 data (St)~slope in field data (Sf )
A two sided t-test with a test significance level of a= 0.05, a
power of 12b= 0.80 and an effect size of d= 0.15 was used. The
total sample size required for showing a significant difference
between the slopes St and Sf was n = 642 isolates for each data type
(field and travellers data) per country.
Logistic regression. For the molecular analysis, a logistic
regression model with time as a linear covariate was fitted to the
prevalence of the mutant isolates (separately, for the pfcrt 76 and
pfdhfr 108 data) for the travellers and field studies, for each country.
Given the probability of the mutant isolates, the observed number
of mutant isolates in each year was assumed to be binomially
distributed. The estimated slope of the fitted logistic regression
curve for the travellers and field data, the 95% confidence intervals
for the slopes and whether the slopes differ significantly from each
other are presented (see figures in the results section).
For the in vitro susceptibility analysis, a Generalized Linear
Model (GLM) with a log-link function was fitted to the travellers
and field data for the period 2000–2011. The slopes of the changes
in CQ susceptibility for the two datasets were assessed to
determine whether they differed significantly from null (0) and
whether they differed significantly from each other.
Software. All statistical analyses were performed using Stata
version 11 for Windows (Stata Corp, College Station, TX, USA)
and R version 2.10 (R – project).
Results
Four African countries had sufficient numbers of field and
traveller derived isolates to allow meaningful comparisons between
the two populations: Senegal, Mali, Cote d’Ivoire and Cameroon.
The characteristics for the field studies are summarised in Table 2
for each publication. A total of 23 studies were included for pfcrt 76
analysis over the 2000–2011 period, mainly from Senegal; 21
studies for pfdhfr 108 analysis for 1996–2010 and 8 studies from
Senegal for the in vitro analysis over the same period. The
characteristics of the patients differed between studies regarding
the population age and the study settings (urban or rural area) but
this heterogeneity was observed for the four countries.
The median patient age for travellers experiencing malaria after
their return to France was 31 years, with 79% older than 15 and
61% of the travellers had visited friends and relatives in endemic
countries for more than one month. Only 38% reported
prophylaxis intake during their travel and most patients presented
with uncomplicated malaria (95%) (Table 3). No differences
among these characteristics were observed among the four
countries except for gender; a majority of travellers to Senegal
and Mali were male.
Between 2000–2011, 2,874 P. falciparum positive isolates were
collected from travellers for analysis of the pfcrt 76 allele prevalence
and 3,351 isolates for analysis of the pfdhfr 108 allele prevalence
between 1996–2011. Between 1996 and 2011, 305 fresh blood
samples were collected from travellers, and tested in Paris or
Marseille to measure susceptibility to CQ in vitro.
Figure 2 and Table 4 summarize the temporal trends in the
prevalence of the pfcrt 76T mutant isolates (associated with CQ
Table 2. Cont.
Country Site Age population Year of study Reference
Bafoussam, Bertoua, Djoum, Garoua,
Hevecam, Manjo, Maroua, Mengang,
Ndop, Ngaoundere, Sangmelima,
Yaounde
,10 ya 1999–03 [70]
Dschang, Fontem, Limbe, Nkambe ,10 ya 2002–03 [71]
Garoua, Mutengene, Yaounde ,5 ya 2004–06 [59]
Yaounde $12 ya 2001–05 [72]
In vitro susceptibility test
chloroquine Senegal Mlomp 1996–98 [73]
Pikine, Dielmo, NDiop All 1996 [74]
Dielmo, NDiop 1997 [75,76]
Pikine $5 ya 2000 [41]
Pikine $18 ya 2001 [42]
Dakar 2002 [44]
Dakar 2009–2010 [77]
doi:10.1371/journal.pone.0077775.t002
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resistance) in each of the targeted countries. The prevalence of the
pfcrt 76T mutant genotype significantly decreased for travellers
between 2000 and 2011 in Senegal (St =20.17, p,10
23), Cote
d’Ivoire (St =20.15, p,10
23) and less dramatically in Cameroon
(St =20.09, p,10
23). However, over that same period, no overall
decrease was observed in isolates from Mali (St =20.01, p = 0.72).
After comparing the slopes of the trends for the isolates from
travellers (St) and from locally studied parasites (Sf), no significant
differences were observed between 2000 and 2011 in Senegal
(St =20.17 versus Sf =20.21, p = 0.58), Mali (St =20.01 versus
Sf = 0.01, p = 0.89), Cote d’Ivoire (St =20.15 versus Sf =20.22,
p = 0.58) and Cameroon (St =20.09 versus Sf = 0.05, p = 0.26)
(Table 4, Figure 2). After performing a power calculation on the
Table 3. Characteristics of travellers with malaria returning from Senegal, Mali, Cote d’Ivoire and Cameroon and reported in France
during the period from 2000 to 2011.
Travellers Senegal (n =1,993)* Mali (n = 2,372)* Cote d’Ivoire (n =4,778 )*
Cameroon
(n=3,272)*
Median age (year) [Min-Max] 30 [0–94] 31 [0–76] 30 [0–83] 33 [0–87]
Gender ratio (Male/Female) 2.47 2.20 1.40 1.15
Chemoprophylaxis
Yes n (%) 746 (38) 959 (41) 1,955 (41) 1,048 (32)
Duration of stay
#2 weeks n (%) 218 (13) 152 (8) 457 (12) 439 (16)
2–4 weeks n (%) 356 (21) 361 (18) 1,150 (30) 868 (33)
1–3 months n (%) 699 (41) 928 (48) 1,221 (32) 679 (25)
.3 months n (%) 428 (25) 498 (26) 1,021 (26) 688 (26)
Purpose of travel
Tourism n (%) 322 (18) 251 (12) 514 (12) 397 (13)
Visit friends and relatives n (%) 1,108 (61) 1,520 (71) 2,482 (58) 1,738 (59)
Severe malaria**
Yes n (%) 136 (7) 123 (5) 225 (5) 177 (5)
*Numbers may not add to totals because of missing information.
**Severe malaria are cases of imported malaria that fulfilled at least one criteria of the WHO clinical and laboratory classification of severity [78].
doi:10.1371/journal.pone.0077775.t003
Figure 2. Observed data, fitted model (by logistic regression) and 95% confidence interval (shaded area) for the prevalence of the
pfcrt 76 mutant isolates from 2000 to 2011 for travellers (red) and field studies (blue) for A-Senegal, B-Mali, C-Cote d’Ivoire and D-
Cameroon. Each data point represents the prevalence of resistant isolates per year for travellers’ data and per study for field studies, where the size
of the circle is proportional to the number of isolates in the sample.
doi:10.1371/journal.pone.0077775.g002
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four previous tests, the probabilities of rejecting the null
hypothesis, St = Sf, when it is false, were between 92 and 96%.
These data derived from studies of parasites from returning
travellers reflected accurately the trends of the prevalence of
molecular markers of CQ resistance that were occurring in the
countries in which the travellers acquired their malaria.
Changes in CQ susceptibility were also assessed using the in vitro
response of isolates. From 1996 to 2011 the geometric mean of the
IC50 for CQ of the isolates tested in vitro decreased in isolates from
travellers and those studied in Senegal (Table 4, Figure 3). The
geometric means of the IC50 values measured for the isolates from
travellers were lower than those measured in Senegal. However,
the slopes showing the trends did not differ significantly
(St =20.05 versus Sf =20.03, p = 0.26) with a power of 94%. In
this case, as well, the data gathered from travellers was an accurate
reflection of the trend among parasite populations in the country
of origin.
The increase of the molecular marker pfdhfr 108N has been
commonly associated with an increase of pyrimethamine resis-
tance for more than fifteen years [23]. When this parameter was
compared between travellers and field-derived isolates, a signifi-
cant increase in the pfdhfr 108N genotype was observed in all 4
countries over the period from 1996–2011: Senegal (St = 0.12,
p,1023), Mali (St = 0.18, p,10
23), Cote d’Ivoire (St = 0.08,
p,1023) and Cameroon (St = 0.21, p,10
23) (Table 4, Figure 4).
For this comparison as well, no significant difference was observed
in the trends of the molecular marker pfdhfr 108N when data from
travellers (St) and field-derived (Sf) isolates were compared for
samples taken between 1996 and 2011: Senegal (St = 0.12 versus
Sf = 0.15, p = 0.39), Mali (St = 0.18 versus Sf = 0.12, p = 0.12), Cote
d’Ivoire (St = 0.08 versus Sf = 0.13, p = 0.48) and Cameroon
(St = 0.21 versus Sf = 0.13, p = 0.75) (Table 4, Figure 3). The powers
of the four comparative analyses ranged between 91 and 97%.
Thus, all three measures of changes in prevalence of molecular
markers and in vitro parasites resistance to CQ and pyrimethamine
demonstrate that information from parasites imported by travellers
was an accurate measure of the changes in parasites within the 4
countries studied.
Discussion
This study suggests that the surveillance of travellers may be
used for monitoring antimalarial drug resistance in endemic
countries. The proof of concept was demonstrated using the
prevalence of two molecular markers, pfcrt 76 and pfdhfr 108, and
in vitro susceptibility for CQ. In this study, no significant difference
between the trends of antimalarial drug resistance for travellers’
and field data were observed over more than 10 years. A decrease
of the prevalence of the pfcrt 76T mutant genotype was observed
over a period of 10 years in travellers returning from Senegal, Cote
d’Ivoire and Cameroon, whilst this prevalence remains stable in
Mali. An increase of mutant genotype isolates for pfdhfr 108 was
observed in the four countries of West and Central Africa. The
in vitro CQ susceptibility results supported the molecular results for
Senegal. The trend in pfcrt 76 is downward while the trend in pfdhfr
108 is upward. The fact that screening travellers was able to detect
temporal trends in opposite directions strengthens the proof of
concept significantly.
Sustainable, reliable and systematic monitoring of drug efficacy
is needed for tracking resistance [24]. Monitoring antimalarial
drug resistance is based on clinical assessment and biological assays
as part of a clinical trial [25]. Since the emergence of resistance to
CQ, and then later to SP, capacities to conduct such monitoring in
endemic countries have substantially improved, but remain very
heterogeneous. In particular regions, human and/or technical
resources are limited and, as such, conducting a clinical trial for
the purpose of surveillance has competed with other high priorities
Table 4. Comparison between travellers and field data for the pfcrt 76 and pfdhfr 108 molecular markers and for the CQ in vitro
susceptibility in Senegal.
Country Travellers Slope [95% CI*] Field Study Slope [95% CI] p-value**
Pfcrt 76 Senegal 20.167 [20.219; 20.115] 20.208 [20.312; 20.105] 0.575
Mali 20.009 [20.082; 0.063] 0.005 [20.106; 0.116] 0.885
Cote d’Ivoire 20.146 [20.215; 20.078] 20.215 [20.463; 0.032] 0.578
Cameroon 20.090 [20.146; 20.033] 0.050 [20.220; 0.321] 0.264
Pfdhfr 108 Senegal 0.117 [0.088; 0.147] 0.148 [0.088; 0.209] 0.386
Mali 0.182 [0.124; 0.240] 0.119 [0.086; 0.152] 0.116
Cote d’Ivoire 0.083 [0.052; 0.113] 0.132 [20.025; 0.289] 0.484
Cameroon 0.213 [0.115; 0.311] 0.130 [20.155; 0.415] 0.753
CQ in vitro analysis Senegal 20.050 [20.085; 20.015] 20.028 [20.059; 0.002] 0.264
*CI = confidence interval,
**The p-value indicates whether the fitted slopes for travellers data and field studies were significantly different from each other.
doi:10.1371/journal.pone.0077775.t004
Figure 3. Observed data, fitted model (by Generalized Linear
Model) and 95% confidence interval (shaded area) for the
in vitro CQ response (IC50) isolates from 1996 to 2011 for
travellers (red) and field studies (blue) from Senegal. Each data
point represents the ln (mean IC50) per year for travellers’ data and per
study for field studies, where the size of the circle is proportional to the
number of isolates in the sample.
doi:10.1371/journal.pone.0077775.g003
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that Ministries of Health must contend with and has not been
systematically conducted.
Previous studies highlight the usefulness of travellers’ surveil-
lance as an early warning detection system for emergence or re-
emergence of communicable diseases [26,27,28]. Travellers’
surveillance has proven in the past to be an effective early alert
system for detecting the emergence of CQ resistance (Table 1).
One strength of using travellers as a sentinel system of resistance
is that detection of clinical therapeutic failure due to resistance is
facilitated in this non immune population with a low risk of re-
infection. Moreover, the French Malaria Reference Centre use
standardized methods for prospectively collecting reliable infor-
mation.
This study does have several limitations. First, due to the
complexity of collecting laboratory data systematically, consistent-
ly and over a long period of time in both populations, travellers
and field studies, only four countries and two molecular markers
have been used in this proof of concept. Second, precise
information regarding the location of infection within each
country could not be collected for P. falciparum infected travellers
returning from endemic countries. However, travellers did not visit
all parts of a country and they were more likely to frequent
particular places such as touristic and/or, or business-oriented
locations. The reported information was highly dependent on
factors such as the areas that were visited, the period of travel,
migration history and the political context in endemic areas. Of
course, these factors can also impact information on exact
locations where patients acquire their infections within the
country, as well. Perhaps more importantly, the travellers in this
work were not representative of the native population in that their
baseline characteristics differ, including age, immune status and
parasitemia before treatment. Finally, especially for the field
studies, different approaches were used for determining the
molecular markers of resistance and the in vitro susceptibility for
CQ. The heterogeneity between methods is encouraging
WWARN to standardise approaches and to develop common
tools like IVART [21].
However, these limitations do not diminish the clarity of the
outcome presented here. Surveillance of parasites from travellers
provided an accurate picture of events occurring in the field. This
does not suggest that this approach should replace studies
conducted in endemic countries. Rather, information from
travellers can be used as an additional surveillance system.
Given the utility, surveillance of travellers can be useful in
tracking resistance to ACTs, as well. Currently, only the response
to the long-acting partner drugs, can be assessed, but if putative
molecular markers are defined, tracking of resistance to the
artemisinin component can also be added. The collaboration
between Ministries of Health in endemic countries and the malaria
reference centres in non-endemic countries for sharing and
validating collected information should be reinforced and facili-
tated.
Due to the length of time between a field study and the
publication of results, data collected from imported cases may be
Figure 4. Observed data, fitted model (by logistic regression) and 95% confidence interval (shaded area) for the prevalence of the
pfdhfr 108 mutant isolates from 1996 to 2011 for travellers (red) and field studies (blue) for A-Senegal, B-Mali, C-Cote d’Ivoire and
D-Cameroon. Each data point represents the prevalence of resistant isolates per year for travellers’ data and per study for field studies, where the
size of the circle is proportional to the number of isolates in the sample.
doi:10.1371/journal.pone.0077775.g004
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available in a more timely manner and, as such, could be used for
early alert of emerging resistance. The complexity of the available
tools for assessing drug efficacy and monitoring resistance
highlights the importance of a standardized and coordinated
approach. The follow-up of imported cases in several non-endemic
countries should also enable the collaborators to track the
evolution of resistance to antimalarial drugs at an international
scale and thus provide novel information of value to policy makers.
The goal of this work was to validate the use of international
traveller surveillance systems, for detecting the emergence of
antimalarial drug resistance and for following resistance trends
where local information is not otherwise available and/or
sufficient. Easy access to reproducible and standardized data
should be implemented. The existing health international,
European or American institutions (WHO, European Centre for
Disease Prevention and Control (ECDC), US Centres for Disease
Control and Prevention (CDC Atlanta) and the different networks
for infectious diseases surveillance in travellers (TropNet Europe,
EuroTravNet, GeoSentinel) should be used for facilitating the
coordination and data sharing between national surveillance
systems [26,27,28].
Conclusions
This study has not shown different trends in antimalarial drug
resistance between travellers and field studies. An international
travellers’ database can be used as an additional surveillance
system to assess and monitor the emergence of drug resistance in
endemic areas where information is limited.
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